UC AKT.ANL. 09/24 SNW/ DE000HD13RD5 /
30/08/2024 21:45:34 | Chg.-0.010 | Bid21:59:30 | Ask21:59:30 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
100.440EUR | -0.01% | 100.420 Bid Size: 70,000 |
100.500 Ask Size: 70,000 |
SANOFI SA INHABER ... | 70.00 - | 27/09/2024 | Call |
GlobeNewswire
14/08
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
GlobeNewswire
13/08
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
12/08
MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter ...
GlobeNewswire
08/08
Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free sur...
GlobeNewswire
07/08
Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
GlobeNewswire
06/08
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D ...
GlobeNewswire
01/08
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
31/07
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2...
GlobeNewswire
25/07
Press Release: Online availability of Sanofi’s half-year financial report for 2024
GlobeNewswire
25/07
Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded
GlobeNewswire
24/07
US Hematologists Express High Unmet Need in Treatments for Warm Autoimmune Hemolytic Anemia and Cold...
GlobeNewswire
18/07
Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, Accord...
GlobeNewswire
17/07
Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transfor...
GlobeNewswire
12/07
FluGen’s Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults Shows ...
GlobeNewswire
11/07
Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Upd...
GlobeNewswire
08/07
Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review ...
GlobeNewswire
03/07
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients...